{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:12Z","timestamp":1789533252528,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL; after \u22651 prior therapy); and by the European Medicines Agency (EMA) for adult patients with relapsed\/refractory (R\/R) MCL and patients with CLL. Ibrutinib treatment can be limited by adverse events (AEs) including atrial fibrillation, arthralgias, rash, diarrhea, and bleeding events, leading to drug discontinuation in 4%\u201326% of patients. Acalabrutinib, a second-generation BTK inhibitor, is approved by the FDA to treat adult patients with CLL\/SLL or MCL (relapsed after 1 prior therapy); and by the EMA to treat adult patients with CLL or R\/R MCL. The most common AE associated with acalabrutinib is headache of limited duration, which occurs in 22%\u201351% of patients, and is mainly grade 1\u20132 in severity, with only 1% of patients experiencing grade \u22653 headache. Furthermore, acalabrutinib is associated with a low incidence of atrial fibrillation. Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients with MCL who have received \u22651 prior therapy, and is under investigation for the treatment of patients with CLL. In the phase 3 SEQUOIA trial in patients with CLL, the most common grade \u22653 AEs were neutropenia\/neutrophil count decreased and infections. This review provides an overview of BTK inhibitor-related AEs in patients with CLL, and strategies for their management.<\/jats:p>","DOI":"10.3389\/fonc.2021.720704","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T02:04:00Z","timestamp":1636337040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice"],"prefix":"10.3389","volume":"11","author":[{"given":"Susan M.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"B1","volume-title":"Imbruvica\u00ae (Ibrutinib) [Prescribing Information]","year":"2020"},{"key":"B2","volume-title":"Imbruvica\u00ae [Summary of Product Characteristics]","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib Versus Temsirolimus in Patients With Relapsed or Refractory Mantle-Cell Lymphoma: An International, Randomised, Open-Label, Phase 3 Study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B7","volume-title":"Calquence\u00ae (Acalabrutinib) [Prescribing Information]","year":"2019"},{"key":"B8","unstructured":"AstraZeneca. Calquence Recommended for Approval in the EU by CHMP for Chronic Lymphocytic Leukaemia2020"},{"key":"B9","volume-title":"Brukinsa","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib Monotherapy for Patients With Treatment Naive Chronic Lymphocytic Leukemia and 17p Deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With the BTK Inhibitor Zanubrutinib: Phase 2, Single-Arm, Multicenter Study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib Monotherapy in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0765-7","article-title":"NR4A Nuclear Receptors Restrain B Cell Responses to Antigen When Second Signals Are Absent or Limiting","volume":"21","author":"Tan","year":"2020","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000026","article-title":"The Regulators of BCR Signalling During B Cell Activation","volume":"1","author":"Wen","year":"2019","journal-title":"Blood Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) Function is Important to the Development and Expansion of Chronic Lymphocytic Leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0","article-title":"The Gene Involved in X-Linked Agammaglobulinaemia is a Member of the Src Family of Protein-Tyrosine Kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-f","article-title":"Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-Linked Agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s Tyrosine Kinase in B Cells and Malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-Generation Inhibitors of Bruton Tyrosine Kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B25","first-page":"483","article-title":"Ibrutinib (Imbruvica): A Novel Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"Pharm Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor With a Differentiated Selectivity and In Vivo Potency Profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and Novel BTK Inhibitors in Clinical Development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent on-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), A Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"JCO2101210","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"B35","article-title":"First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","author":"Hillmen","year":"2021","journal-title":"Eur Hematol Assoc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol"},{"key":"B37","unstructured":"HelwickC\n          Zanubrutinib vs Ibrutinib in Relasped\/Refractory CLL\/SLL: ALPINE Trial2021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.7009","article-title":"Highlights From ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia","volume":"27","author":"Dolan","year":"2020","journal-title":"Curr Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.6004\/jnccn.2020.0006","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1188\/20.CJON.392-398","article-title":"Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma","volume":"24","author":"Badillo","year":"2020","journal-title":"Clin J Oncol Nurs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.clml.2020.02.001","article-title":"Ibrutinib-Associated Arthralgias\/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes","volume":"20","author":"Rhodes","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/brainsci10010030","article-title":"Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache","volume":"10","author":"Carmine Belin","year":"2020","journal-title":"Brain Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001049","article-title":"High Incidence of Atrial Fibrillation in Patients Treated With Ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16859","article-title":"High Prevalence and Incidence of Cardiovascular Disease in Chronic Lymphocytic Leukaemia: A Nationwide Population-Based Study","volume":"190","author":"Larsson","year":"2020","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4022\/jafib.154","article-title":"Atrial Fibrillation: The New Epidemic of the Ageing World","volume":"1","author":"Aronow","year":"2009","journal-title":"J Atr Fibrillation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune Cytopenias in Chronic Lymphocytic Leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000617","article-title":"Oral Bruton Tyrosine Kinase Inhibitors Block Activation of the Platelet Fc Receptor CD32a (FcgammaRIIA): A New Option in HIT","volume":"3","author":"Goldmann","year":"2019","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207183","article-title":"Differences and Similarities in the Effects of Ibrutinib and Acalabrutinib on Platelet Functions","volume":"104","author":"Series","year":"2019","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13148","article-title":"The Effect of Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors on Collagen-Induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC)","volume":"101","author":"Chen","year":"2018","journal-title":"Eur J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-Specific Concentrations of Ibrutinib and Acalabrutinib Delays But Does Not Block Platelet Aggregation Mediated by Glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14660","article-title":"Use of Anticoagulants and Antiplatelet in Patients With Chronic Lymphocytic Leukaemia Treated With Single-Agent Ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-120779","article-title":"A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912) [Abstract]","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1182\/blood-2019-127102","article-title":"Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\u2265 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL) [Abstract]","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B59","unstructured":"SeymourC\n          Acalabrutinib Demonstrates Activity in Frontline CLL2019"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S250823","article-title":"Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia","volume":"15","author":"Rhodes","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B61","volume-title":"NCCN Guidelines Version 4.2021. Chronic Lymphocytic Leuekemia\/Small Lymphocytic Lymphoma","year":"2021"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.720704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T02:04:06Z","timestamp":1636337046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.720704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":61,"alternative-id":["10.3389\/fonc.2021.720704"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.720704","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"article-number":"720704"}}